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1) Institute of Microbiology and 2) Infectious Diseases Service, University of Lausanne and University Hospital Center, Lausanne, SwitzerlandAbstractWhen a bloodstream infection (BSI) is suspected, most of the laboratory results—biochemical and haematologic—are available within the
ﬁrst hours after hospital admission of the patient. This is not the case for diagnostic microbiology, which generally takes a longer time because
blood culture, which is to date the reference standard for the documentation of the BSI microbial agents, relies on bacterial or fungal growth.
The microbial diagnosis of BSI directly from blood has been proposed to speed the determination of the etiological agent but was limited by
the very low number of circulating microbes during these paucibacterial infections. Thanks to recent advances in molecular biology, including
the improvement of nucleic acid extraction and ampliﬁcation, several PCR-based methods for the diagnosis of BSI directly from whole blood
have emerged. In the present review, we discuss the advantages and limitations of these new molecular approaches, which at best
complement the culture-based diagnosis of BSI.
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E-mail: Gilbert.Greub@chuv.chIntroductionA large majority (approximately 70%) of the medical decisions
for the management of patients are taken on the basis of lab-
oratory results. Several key results such as biochemistry and
haematology can be provided within the day of entrance into
the hospital [1]. There is a need to accelerate the diagnosis of
microbiologic analysis. This is particularly true in the case of
sepsis, for which appropriate decisions and treatments should
be provided in a critical time window of 6 hours to reduce
morbidity and mortality [2]. Culture-based diagnosis remains
the reference standard in identifying the causative agent when a
bloodstream infection (BSI) is suspected. However, culture-
based diagnosis is not convenient for infections as a result of
uncultivable microorganisms or when an antibiotic treatment isClinical Microbiology and Infection © 2015 European Society of Cstarted before the sampling. In case of severe disease such as
BSI, the early introduction of an efﬁcient anti-infectious treat-
ment has a major impact on patient outcomes. The microbial
documentation of the BSI is essential to ensure that the anti-
infectious treatment is adequate. In addition, microbial docu-
mentation associated with susceptibility testing permits a
reduction in the spectrum of administrated anti-infectious
drugs. Such de-escalation limits the negative impact of com-
bined treatments and/or broad-range antibiotics in term of
adverse effects and in terms of selection pressure on
commensal microbes, with consequent increase in prevalence
of resistant strains. A microbial diagnosis in less than 6 hours
thus would be beneﬁcial for the optimal management of pa-
tients [1].
The microbial documentation of BSI generally starts by blood
culture (BC) because of the low quantity of microbes in the
blood during such infections. BCs have been continuously
optimized to increase the sensitivity and speciﬁcity of micro-
organism recovery. Nevertheless, in 50% of cases, BSIs occur
with negative BC, which can delay the introduction of an
adequate anti-infectious therapy [3,4]. This can be due to very
low number of circulating microbes, to fastidiousClin Microbiol Infect 2015; 21: 323–331
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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treatment initiated before blood sampling. Thus, new diagnosis
approaches are warranted.
The evolution of molecular biology in the last decades— in
particular the evolution of nucleic acids extraction techniques
and ampliﬁcation methods, as well as multiplexed PCR
methods—provide tools to detect etiological agents of sepsis
that would otherwise remain undetected. Moreover, to apply
these molecular methods directly on whole blood does not
only circumvent the limiting culture step but also provides a
much lower turnaround time [5,6]. In the present review, we
discuss the advantages and limitations of these new molecular
approaches that at best complement the culture-based diag-
nosis of BSIs.Blood as a sampleThe microbial diagnosis of BSI directly from whole blood has
been limited for a long time by the low number—1 to 10 CFU/
mL—of circulating organisms during such infection [7–10].
This number is the result of quantitative analysis obtained by
conventional plating methods and might underestimate the true
number of bacterial cells present in the blood. Indeed, CFU
refers to living organism that can be recovered by culture andClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectthus tightly correlates with culture-based diagnosis methods,
but not culture-independent methods. For nucleic acid
methods such as PCR, the number of genome copies (GC)
present in a sample is more relevant than the number of CFU
recovered after plating. Indeed, the number of GC also includes
DNA from dead bacterial cells, from clumping cells and from
bacteria engulfed by circulating phagocytes. On the basis of
results obtained with PCR/electrospray ionization mass spec-
trometry (ESI-MS) and on data from the literature obtained
with quantitative PCR, Bacconi et al. [11] estimated that during
a BSI, there are about 103 to 104 GC/mL, which is a bacteria
load above the detection limit of most PCRs (Fig. 1).
Another limiting factor of whole blood is the high quantity of
human DNA that could interfere with primers and probes
binding during PCR. The quantity of human DNA can be
reduced by removing white blood cells before DNA extraction
or by using methods for speciﬁc removal or degradation of
human DNA after extraction of nucleic acids. Moreover, blood
is prone to inhibit PCR reaction. In many cases, a simple dilu-
tion of the sample can alleviate the inhibition; nevertheless,
some well-known PCR inhibitors such as iron, immunoglobulins
and heparin should be removed or avoided altogether (Fig. 1).
Iron that is mainly associated with haemoglobin from erythro-
cytes and lactoferrin from leucocytes can inhibit PCR by spe-
ciﬁcally inhibiting DNA synthesis [12–15]. Immunoglobulin (inFIG. 1. Blood as a sample for mi-
crobial diagnosis during BSI. The
main components of the blood that
affect the molecular diagnosis of BSI
are represented. The number of
circulating bacteria during BSI is
estimated to be 1 to 10 CFU/mL.
Data obtained with quantitative PCR
demonstrated that during BSI, there
are about 103 to 104 GC/mL due to
both DNA from living bacteria and
DNA from clamping bacteria. Some
PCR inhibitors such as iron, immu-
noglobulin and heparin are repre-
sented. Iron that is mainly associated
with haemoglobin from erythrocytes
and lactoferrin from leucocytes can
inhibit PCR due to its inhibition of
DNA synthesis Immunoglobulin, in
particular IgG able to bind single-
strand DNA, can also inhibit PCR.
Anticoagulants such as heparin must
be avoided.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 323–331
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inhibit PCR [16]. Anticoagulants such as heparin have also to be
avoided to reduce the risk of PCR inhibition [17]. EDTA
(ethylenediaminetetraacetic acid) is more suitable. In addition,
several uncharacterized inhibition mechanisms may have a
major impact but may remain undetected. They can be revealed
by using internal inhibition controls [18–20].Advantages of molecular diagnosis directly
from bloodOne of the main advantages of working directly from blood is
the reduced time to results. Firstly, microorganism detection is
independent of enrichment via BC; indeed, the time to posi-
tivity of BC can vary from hours (6 to 8 hours for fast-growing
bacteria) to days (slow-growing bacteria, fungi, Mycobacterium
spp.). Secondly, microorganism identiﬁcation is culture inde-
pendent, unlike most phenotypic methods. Finally, culture-
independent methods give a snapshot of what is going on in
the bloodstream. The times to results of the available auto-
mated systems are presented in Table 1.
The low detection limit of speciﬁc PCRs can potentially make
them more sensitive than BC. However, the intrinsic high
sensitivity of the PCR is largely counterbalanced by the actual
low input volume used for PCR, generally less than 500 μL of
blood compared to BC broths, which are generally inoculatedTABLE 1. Main commercially available systems for identiﬁcation o
System Method
Time to
result
(hours)
Blood
volume
(mL)
Microorganism
coverage
SepsiTest
Molzym, Bremen,
Germany
Broad-range PCR +
sequencing
6 1–10a >345 bacteria (Gram
positive and Gram
negative) and fungi
SeptiFast
Roche Molecular
System, Basel,
Switzerland
Multiple broad-range
real-time PCR
3.5–5 1.5 6 Gram positive,
8 Gram negative,
5 fungi
MagicPlex
Seegene, Seoul,
Korea
Multiple PCR +
multiplex real-time
PCR
3–5 1 21 bacteria (Gram
positive and Gram
negative) at species
level (90 at genus
level), 6 fungi
VYOO
SIRS-Lab, Jena,
Germany
Multiplex PCR +
electrophoresis
8 5 14 Gram positive,
18 Gram negative,
7 fungi
PLEX-ID, Abbott
Molecular, Carlsbad,
CA, USA
Multiplex broad-range
PCR/ESI-MS
6 1.25–5c Up to 800 (Gram
positive, Gram
negative, fungi)
ESI-MS, electrospray ionization mass spectrometry.
aWith an additional kit.
bWith an additional test for patient with positive detection of Staphylococcus aureus.
cFor the latest version.
dDepending on the sample volume (1.25 versus 5).
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiologywith 8 to 10 mL of blood and are performed in parallel with a
total of four to six bottles [21]. Thus, PCR-based approaches
are mainly useful when it is difﬁcult to obtain a high volume of
blood—paediatric patients, for instance. In addition, molecular
methods are not very sensitive to antibiotic treatment, whereas
BC requires living organisms. Thus, PCR is much less affected
by previous empirical antibiotic treatment that is generally
provided to patients with symptomatic BSI.
Quantitative real-time PCR may help interpreting positive
results because contamination is generally characterized by a
very low amount of bacteria. However, because bacteraemia is
often a paucibacterial infection, quantitative data are mainly
useful when a high bacteria load is documented (Fig. 1).
Quantiﬁcation is also useful in the case of polymicrobial infec-
tion in order to determine the relative abundance of each
pathogen. Quantiﬁcation of the bacteria load can also provided
some indirect information regarding infection severity [22,23].
The evolution of the number of GC per millilitre could be
useful for the follow-up of BSI after initiating an anti-infectious
treatment.Inconvenience of molecular diagnostic
directly from bloodBecause of their high sensitivity, PCRs are exposed to
contamination and may result in false-positive results.f microbes directly from blood samples
Resistance
and
virulence
markers
Sensitivity,
speciﬁcity,
and correlation
with conventional
methods (%) Comments Ref.
0 21–87, 85–96, NR Pros: can be used in other
sterile samples; Cons:
variable sensitivity and
speciﬁcity
[43,56,58–61]
mecAb 43–95, 60–100, 43–83 Pros: time to result; Cons:
variable sensitivity and
speciﬁcity, no
quantiﬁcation
[35–53,74]
mecA, vanA/B 37–65, 77–92, 73 Pros: fast; Cons: limited
number of studies,
succession of reaction
and device, no
quantiﬁcation
[55,56]
0 NR, NR, 70 Pros: highly sensitive;
Cons: limited number
of studies, several
manual steps
[59,63,75]
mecA, blaKPC,
vanA/B
50–91d, 98–99, 79–97 Pros: universal, detection
of mixed bacterial
populations,
semiquantitative;
Cons: no
interventional studies
[11,76,77]
and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 323–331
326 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIContamination can be brought by DNA from the environment
or from PCR reagents despite using nucleic acid– free com-
pounds. False-positive PCR ﬁndings can be due to circulating
cell-free DNA from dead bacteria or fungal DNA in the
absence of infection—DNAemia rather than a true bacteremia
or fungemia (Fig. 1, Table 2) [24,25]. In addition, an infection
successfully controlled by the immune system or by an efﬁcient
anti-infectious therapy will release pathogenic DNA that can
persist several days in the blood.Species-speciﬁc PCRs on bloodSpeciﬁc PCRs targeting particular pathogens have been
increasingly used by microbiologists, especially for the diag-
nosis of BC-negative endocarditis and other endovascular
infections. Pathogen-speciﬁc PCRs that can be applied directly
on blood include Bartonella PCR [26], Coxiella PCR [27],
and Whipple PCR [28,29]. Species-speciﬁc PCRs may also
be applied to blood samples for the diagnostic of pri-
moinfections for pathogens that are circulating during the
earliest phase of infection, i.e. Coxiella spp. [27] and Whipple
[29]. These may be used as monoplex PCR or multiplex
format. In addition to such speciﬁc agents of endovascular
infections, common cause of bacteremia such as Escherichia
coli, Staphylococcus aureus and Streptococcus spp. are increas-
ingly targeted by new molecular approaches able to detect
several pathogens and able to test resistance genes at the
same time. These approaches include PCR-based assays as
well as various postampliﬁcation identiﬁcation techniques
(sequencing, electrophoresis and electrospray mass spec-
trometry) (Fig. 2, Table 2).TABLE 2. Pros and cons of microbial diagnosis of bloodstream
infection directly from blood samples
Pros
 Speed.
 High sensitivity.
 High speciﬁcity: when associated with quantiﬁcation.
 Detection of noncultivable organisms.
 Resistance (virulence) traits: rapid and speciﬁc for the detection of
monofactorial mechanisms.
Cons
 Unable to replace blood culture.
 Not fully automated.
 Sample volume: not standardization.
 Sensitive to contamination.
 Resistance (virulence) traits: unable to characterize multifactorial mechanisms.
 New work ﬂow need to be deﬁned to associate culture-dependent and
culture-independent methods.
 Clinical impact: lack of interventional studies.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectIdentiﬁcation during nucleic acid
ampliﬁcation: multiplex real-time PCRLightCycler SeptiFast
The LightCycler SeptiFast (Roche Molecular System, Basel,
Switzerland) is an automated system that can identify 19 path-
ogens (eight Gram-negative bacteria, six Gram-positive bacteria
and ﬁve fungi) and the mecA gene associated with methicillin
resistance in S. aureus from 1.5 mL of whole blood in 3.5 to 5
hours (Table 1). DNA of pathogens is ampliﬁed using multiple
broad-range PCRs. The identiﬁcation at the species level is
provided by the analysis of the melting curves of the speciﬁc
probes. The short time to result, 5 to 8 hours, is one of the main
advantages of the SeptiFast compared to BC time to positivity
(Fig. 2, Table 1) [30–32]. A large literature on the performance
of SeptiFast is available because this device was commercialized
in 2004. Despite its good analytic sensitivity—3 to 30 CFU/mL
for bacteria and 100 CFU/mL for fungi [33,34]—the clinical
sensitivity (43% to 95%) and speciﬁcity (60% to 100%) are var-
iable [35–53]. This could be due to the different selected pools
of patients studied. The SeptiFast and BC are complementary
because they correlate at rates of only 43% to 83%. All the other
molecular-based diagnosis methods from whole blood also
display a limited correlation with microbe identiﬁcation from
BC, with the exception of the PLEX-ID system (Abbott Mo-
lecular, Carlsbad, CA, USA) (Table 1). Thus, these PCR-based
methods could not replace BC but are complementary to
culture-based diagnosis. Even the PLEX-ID, which exhibits a
good correlation with BC-based diagnosis, should be considered
a complementary approach because antibiotic susceptibility
testing relies on the availability of strains recovered by culture.
The SeptiFast performs a semiquantitative analysis rather than
a quantitative analysis. High cutoffs used for the interpretation of
potential contaminants such as coagulase-negative staphylococci
or streptococci might lead to false-negative results [54]. While
the limited number of pathogens (n = 19) detected by the
SeptiFast is expected to represent more than 90% of the path-
ogens found in BSI, only one resistance gene, mecA, is detected.
MagicPlex Sepsis
The MagicPlex Sepsis Test (Seegene, Seoul, Korea) is a multi-
step automated system that associates conventional PCR and
real-time PCR. After DNA extraction, a ﬁrst conventional PCR
ampliﬁes microbes DNA. Pathogens are identiﬁed in a subse-
quent step using real-time PCRs. This system allows the
detection of more than 90 pathogens at the genus level,
including 25 pathogens at the species level (19 bacteria and six
fungi) and the resistance genes mecA, vanA and vanB. The
starting volume is 1 mL. The MagicPlex, the most recentious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 323–331
FIG. 2. Nucleic acid methods for the microbial diagnosis of BSI, BC-independent and BC-dependent methods. Nucleic acid–based methods have
shortened the time to result BSI diagnosis. In the absence of microbial documentation of the etiologic agent of the BSI, anti-infectious treatments are
initiated on the basis of clinical and epidemiologic information. Diagnosis directly from blood samples could shorten the length of empiric treatment.
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the fastest system, with a time to result of between 3 to 5
hours, even though it includes several steps and devices.
However, it is limited by the low number of pathogens iden-
tiﬁed at the species level (n = 21), by the absence of quantiﬁ-
cation and by questionable sensitivity. Indeed, the studies
published so far report a sensitivity ranging from 37% to 65%
and a speciﬁcity ranging from 77% to 92% [55,56].Identiﬁcation after nucleic acid ampliﬁcationPCR and sequencing: SepsiTest
The SepsiTest (Molzym, Bremen, Germany) is a semiautomated
system based on broad-range PCRs using universal primers that
target bacterial and fungal rRNA. The amplicons are sequenced
and analysed by BLAST (Basic Local Alignment Search Tool) to
provide identiﬁcation at the species level (99% of identity) or
genus level (97%). This approach allows the identiﬁcation of
345 pathogens (bacteria and fungi). The advantages of the
SepsiTest are the low blood volume needed (2 × 1 mL) and the
fact that it can be used on other sterile body ﬂuids [57,58]. TheClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologymain limitation is that the SepsiTest includes several steps: (a)
nonautomated DNA extraction, (b) PCR ampliﬁcation, (c)
sequencing and (d) online sequence analysis. As a consequence,
the time to result is ranging from 8 to 12 hours and the risk of
contamination is increased. The performances of this assay are
variable, with a sensitivity ranging from 21% to 85% and a
speciﬁcity ranging from 58% to 95% [43,56,58–61]. The cur-
rent device does not include the detection of any resistance
gene.
PCR and electrophoresis: VYOO
The VYOO system (SIRS-Lab, Jena, Germany) is based on mi-
crobial DNA ampliﬁcation using multiple PCRs that target the
16S rRNA encoding gene followed by an electrophoresis on an
agarose gel that allows pathogen identiﬁcation based on the
analysis of the amplicon pattern with an approximate time to
results of 8 hours [62]. After bead-assisted nucleic acid
extraction, there is a step of microbial DNA enrichment based
on the methylation difference between microbial DNA and
human DNA and a chromatographic afﬁnity analysis. In some
studies, the VYOO system provided better results than BC
when using clinical information and markers such asand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 323–331
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due to a low detection limit (3 to 10 CFU/mL) associated with
the large sample volume used (5 mL). A limitation of the VYOO
system is the number of pathogens detected at the species level
(34 bacteria and seven fungi) and the low speciﬁcity of the
electrophoresis-based identiﬁcation.
PCR/ESI-MS analysis
The PLEX-ID (Abbott Molecular) is the only molecular device
considered to be universal. It can detect and identify up to 800
pathogens, including Gram-positive bacteria, Gram-negative
bacteria and fungi. The PLEX-ID associates microbe detection
by PCR and amplicon analysis by ESI-MS. The universality of the
PLEX-ID is brought by the ampliﬁcation of microbial DNA
using multiple broad-range PCRs that target rRNA genes and
other conserved region of bacteria and fungi genomes. Nine
pairs of primers are sufﬁcient to cover the prokaryote kingdom,
and four pairs are sufﬁcient to detect Candida species; four
additional pairs of primers can detect the resistance genes
mecA, blaKPC, vanA and vanB. The primers speciﬁcally bind on
conserved sequences that surround polymorphic regions. The
identiﬁcation of the pathogen at the species level relies on the
analysis of the base composition, A, C, G and T of the amplicon
or amplicons rather than the base sequence [65,66]. The base
composition is obtained by the integration of four parameters:
the exact mass of the amplicon measured by ESI-MS, the length
of the amplicon, the mass of each base and the complementarity
rules of DNA. The base composition of each amplicon is then
compared to a database which provides the identiﬁcation of the
pathogen. The accuracy of the identiﬁcation is dependent on
the richness of the database. One of the advantages of the
PLEX-ID is the short time to results, which is provided by the
use of ESI-MS rather than Sanger sequencing (1 minute vs.
several hours). In addition, the use of speciﬁc primers rather
than degenerated primers explains the good analytic sensitivity
of this technique. While the ﬁrst version of the PLEX-ID was
designed for 1.25 mL of samples [76,77], an updated version
now accepts up to 5 mL of blood. Together with an optimized
DNA extraction method speciﬁc for whole blood [67,68], the
limits of detection of the PLEX-ID are 16 CFU/mL for bacteria
and 4 CFU/mL for Candida spp. [11].
This procedure was evaluated in a prospective study
involving 331 patients with suspicion of BSI [11]. For each pa-
tient, two blood vials (one aerobic and one anaerobic) were
inoculated with 5 mL of whole blood. From the same veni-
puncture, another blood sample (5 mL) was collected for PCR/
ESI-MS analysis. The PCR/ESI-MS displayed 83% sensitivity and
94% speciﬁcity compared to BC. Interestingly, this corre-
sponded to 35 positive specimens (10.6%) by PCR/ESI-MS and
18 positive by culture (5.4%). In the absence of any method toClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectinvestigate the cases positive by PCR/ESI-MS and negative by
culture, a second aliquot was analysed using PCR/ESI-MS.
Almost all the identiﬁcations were conﬁrmed using a second
aliquot and thus were considered to be truly positive, which
increased the sensitivity to 91% and the speciﬁcity to 99% [11].
The prospective study performed by Lafﬂer et al. [68] on 442
patients with negative BC reported 33 cases positive using PCR/
ESI-MS. On the basis of the medical chart, these 33 cases were
considered to be true BSIs.
The PLEX-ID contains an internal control for the quantita-
tive analysis, which facilitates the interpretation of positive re-
sults [68,69]. This quantiﬁcation also helps the interpretation of
polymicrobial infections, as the PLEX-ID can identify several
microorganisms within the same sample [70–73]. It should be
noted that the PLEX-ID is a versatile system that can be used on
a broad range of samples, both sterile and not, which is an
important advantage compared to all other methods.Resistance and virulenceIn case of BSI, the documentation of the incriminated pathogen
allows the adjustment of the anti-infectious therapy. In many
cases, microbial identiﬁcation helps to reduce the spectrum of
the empiric treatment. Nevertheless, for pathogens with
frequent multidrug resistance, i.e. some Enterobacteriaceae,
nonfermenting Gram-negative bacteria or Staphylococcus spp.,
antibiotic susceptibility testing is mandatory. Molecular methods
are sensitive and speciﬁc to detect resistance when the mecha-
nism is monofactorial, i.e. methicillin resistance in staphylococci
or vancomycin resistance in Enterococcus spp. However, in many
cases, the resistancemechanisms aremultifactorial (such as efﬂux
pumps with or without genetic modiﬁcation of the antibiotic
target). For suchmechanisms, phenotypic antibiotic susceptibility
testing remains mandatory. Pathogens with frequent multidrug
resistance to antibiotics, such as methicillin-resistant Staphylo-
coccus aureus or extended-spectrum β-lactamase– or
carbapenemase-producing Gram-negative bacteria, have been
extensively studied because they have been associatedwithmajor
outbreaks and treatment failure. The PLEX-ID detects the mecA
gene, the blaKPC gene and the genes vanA and vanB. MagicPlex
detects themecA gene and the gene vanA and vanB (Table 1). Using
an additional test, the mecA gene can be detected with the Sep-
tiFast system in with S. aureus bacteremia.Cost of molecular diagnosis methodsThe ideal diagnosis method should be, sensitive, speciﬁc, fast
and cost-effective. According to Afshari et al. [6], the cost ofious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 323–331
CMI Opota et al. Diagnosis of bacteremia directly from blood 329the current available systems (i.e. cost of the machine itself)
ranges from approximately US$75,000 for the SeptiFast to
more than US$200,000 for the PLEX-ID; the SepsiTest and the
VYOO systems have estimated costs between US$75,000 and
US$200,000. To these machine costs, laboratory managers
should add into their business plan the cost of reagents, which
may prove to be very high if the test is widely used [6]. The
molecular diagnosis of BSI from whole blood is designed to
reduce the turnaround time and to increase the sensitivity of
microbial documentation. This could have a signiﬁcant impact
on patient management, especially for patients with severe
diseases, such as septic shock, for immunocompromised pa-
tients and for neonates. This should be determined in a cost–
beneﬁt analysis, which, as a result of practical difﬁculties in
precisely assessing the beneﬁts, is still lacking.Conclusions and future researchThe technologies that are currently in use for the microbial
diagnosis of BSI directly from blood and that are described
herein have the potential to dramatically reduce the turnaround
time of microbial diagnosis. In addition, some of these new
molecular technologies display high sensitivity and high speci-
ﬁcity. Molecular methods may have an added value in cases of
severe sepsis and when an antibiotic treatment has been started
before sampling. However, there is a need for interventional
studies to estimate the impact that these technologies will have
on the management of sepsis in routine practice.
The limited correlation between identiﬁcation obtained by
molecular diagnostic methods directly from whole blood and
BC-based methods suggest that these two methods are
complementary. Thus, molecular diagnosis directly from
whole blood samples is unlikely to replace BC, and new work
ﬂows that associate both technologies must be designed and
implemented for diagnostic laboratories. In addition, guide-
lines that include the number of samples and the frequency of
sampling have to be deﬁned. The volume of blood should be
standardized among the different devices, which would facil-
itate performance comparison and, most importantly, would
facilitate the interpretation of positive results by both mi-
crobiologists and clinicians (contamination, DNAemia or
bacteremia).
The emergence of molecular diagnostic tools to detect
pathogens directly from whole blood should be accompanied
by studies on the persistence/clearance of DNA in blood. This
could provide an objective element on interpreting positive
DNA detection and classifying BSI as transient, persistent or
sustained bacteremia.Clinical Microbiology and Infection © 2015 European Society of Clinical MicrobiologyThe new molecular techniques allow us to go faster and
further in BSI diagnosis. Some efforts still need to be under-
taken to overcome the existing obstacles of these methods.
Clinical microbiology is in the ﬁnal stretch to reach the goal of
providing an efﬁcient sepsis diagnosis directly from blood,
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